Linked Life Data

7540220

Source:http://linkedlifedata.com/resource/pubmed/id/7540220

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7540220rdf:typepubmed:Citationlld:pubmed
pubmed-article:7540220lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:7540220lifeskim:mentionsumls-concept:C0079459lld:lifeskim
pubmed-article:7540220lifeskim:mentionsumls-concept:C0023467lld:lifeskim
pubmed-article:7540220lifeskim:mentionsumls-concept:C0001143lld:lifeskim
pubmed-article:7540220lifeskim:mentionsumls-concept:C0010711lld:lifeskim
pubmed-article:7540220lifeskim:mentionsumls-concept:C0015133lld:lifeskim
pubmed-article:7540220lifeskim:mentionsumls-concept:C0026259lld:lifeskim
pubmed-article:7540220lifeskim:mentionsumls-concept:C1707455lld:lifeskim
pubmed-article:7540220lifeskim:mentionsumls-concept:C0205195lld:lifeskim
pubmed-article:7540220pubmed:issue3lld:pubmed
pubmed-article:7540220pubmed:dateCreated1995-7-14lld:pubmed
pubmed-article:7540220pubmed:abstractTextWe used a new chemotherapy regimen for the treatment of 18 consecutive patients with relapsed AML. The regimen consisted of low-dose cytosine arabinoside (Ara-C), low-dose aclarubicin and concurrent use of G-CSF (CAG regimen). Fifteen out of 18 patients (83%) achieved complete remission (CR). Median CR duration and median survival were 6 months and 15 months, respectively. These results were similar to those of previously reported salvage therapies for relapsed AML including intensive chemotherapy consisting of intermediate-dose Ara-C and sequential mitoxantrone with or without etoposide (MC/MEC), which we previously adopted. Myelosuppression and non-hematological toxicities were apparently lower and less frequent compared to MC/MEC. The CAG regimen seems promising for the treatment of relapsed AML with its low toxicity contributing to a high quality of life for the patient.lld:pubmed
pubmed-article:7540220pubmed:languagejpnlld:pubmed
pubmed-article:7540220pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7540220pubmed:citationSubsetIMlld:pubmed
pubmed-article:7540220pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7540220pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7540220pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7540220pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7540220pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7540220pubmed:statusMEDLINElld:pubmed
pubmed-article:7540220pubmed:monthMarlld:pubmed
pubmed-article:7540220pubmed:issn0485-1439lld:pubmed
pubmed-article:7540220pubmed:authorpubmed-author:SaitoKKlld:pubmed
pubmed-article:7540220pubmed:authorpubmed-author:ArimuraHHlld:pubmed
pubmed-article:7540220pubmed:authorpubmed-author:NoguchiMMlld:pubmed
pubmed-article:7540220pubmed:authorpubmed-author:YamadaKKlld:pubmed
pubmed-article:7540220pubmed:authorpubmed-author:FurusawaSSlld:pubmed
pubmed-article:7540220pubmed:authorpubmed-author:KoikeTTlld:pubmed
pubmed-article:7540220pubmed:authorpubmed-author:SakumaHHlld:pubmed
pubmed-article:7540220pubmed:authorpubmed-author:AoyagiAAlld:pubmed
pubmed-article:7540220pubmed:authorpubmed-author:WagaKKlld:pubmed
pubmed-article:7540220pubmed:authorpubmed-author:YamatoHHlld:pubmed
pubmed-article:7540220pubmed:issnTypePrintlld:pubmed
pubmed-article:7540220pubmed:volume36lld:pubmed
pubmed-article:7540220pubmed:ownerNLMlld:pubmed
pubmed-article:7540220pubmed:authorsCompleteNlld:pubmed
pubmed-article:7540220pubmed:pagination165-74lld:pubmed
pubmed-article:7540220pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:7540220pubmed:meshHeadingpubmed-meshheading:7540220-...lld:pubmed
pubmed-article:7540220pubmed:meshHeadingpubmed-meshheading:7540220-...lld:pubmed
pubmed-article:7540220pubmed:meshHeadingpubmed-meshheading:7540220-...lld:pubmed
pubmed-article:7540220pubmed:meshHeadingpubmed-meshheading:7540220-...lld:pubmed
pubmed-article:7540220pubmed:meshHeadingpubmed-meshheading:7540220-...lld:pubmed
pubmed-article:7540220pubmed:meshHeadingpubmed-meshheading:7540220-...lld:pubmed
pubmed-article:7540220pubmed:meshHeadingpubmed-meshheading:7540220-...lld:pubmed
pubmed-article:7540220pubmed:meshHeadingpubmed-meshheading:7540220-...lld:pubmed
pubmed-article:7540220pubmed:meshHeadingpubmed-meshheading:7540220-...lld:pubmed
pubmed-article:7540220pubmed:meshHeadingpubmed-meshheading:7540220-...lld:pubmed
pubmed-article:7540220pubmed:meshHeadingpubmed-meshheading:7540220-...lld:pubmed
pubmed-article:7540220pubmed:meshHeadingpubmed-meshheading:7540220-...lld:pubmed
pubmed-article:7540220pubmed:meshHeadingpubmed-meshheading:7540220-...lld:pubmed
pubmed-article:7540220pubmed:meshHeadingpubmed-meshheading:7540220-...lld:pubmed
pubmed-article:7540220pubmed:meshHeadingpubmed-meshheading:7540220-...lld:pubmed
pubmed-article:7540220pubmed:meshHeadingpubmed-meshheading:7540220-...lld:pubmed
pubmed-article:7540220pubmed:year1995lld:pubmed
pubmed-article:7540220pubmed:articleTitle[Comparison of low-dose cytosine arabinoside and aclarubicin in combination with granulocyte colony-stimulating factor to intermediate-dose cytosine arabinoside and mitoxantrone with or without etoposide in the treatment of relapsed acute myeloid leukemia].lld:pubmed
pubmed-article:7540220pubmed:affiliationThird Department of Internal Medicine, Dokkyo University School of Medicine.lld:pubmed
pubmed-article:7540220pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7540220pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:7540220pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:7540220pubmed:publicationTypeEnglish Abstractlld:pubmed